Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

This study has been completed.
Sponsor:
Collaborators:
Kowa Pharmaceuticals America, Inc.
Eli Lilly and Company
Information provided by (Responsible Party):
Kowa Research Institute, Inc.
ClinicalTrials.gov Identifier:
NCT01301066
First received: February 18, 2011
Last updated: March 27, 2014
Last verified: March 2014
Results First Received: February 10, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Dyslipidemia
Interventions: Drug: Pitavastatin
Drug: Pravastatin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Pitavastatin 4 mg QD Pitavastatin: Pitavastatin 4 mg QD
Pravastatin 40 mg QD Pravastatin: Pravastatin 40 mg QD

Participant Flow:   Overall Study
    Pitavastatin 4 mg QD   Pravastatin 40 mg QD
STARTED   126   126 
COMPLETED   99   91 
NOT COMPLETED   27   35 
Lost to Follow-up                5                11 
Protocol Violation                8                7 
Withdrawal by Subject                4                9 
Adverse Event                6                6 
Sponsor Decision                2                1 
Physician Decision                0                1 
Other                2                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Pitavastatin 4 mg QD Pitavastatin: Pitavastatin 4 mg QD
Pravastatin 40 mg QD Pravastatin: Pravastatin 40 mg QD
Total Total of all reporting groups

Baseline Measures
   Pitavastatin 4 mg QD   Pravastatin 40 mg QD   Total 
Overall Participants Analyzed 
[Units: Participants]
 126   126   252 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   126   126   252 
>=65 years   0   0   0 
Gender 
[Units: Participants]
     
Female   20   15   35 
Male   106   111   217 
Region of Enrollment 
[Units: Participants]
     
United States   126   126   252 


  Outcome Measures

1.  Primary:   Change of Fasting Serum Low-density Lipoprotein Cholesterol (LDL-C) at 12 Weeks   [ Time Frame: 12 weeks minus baseline ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Roger Morgan, MD, FACS
Organization: Kowa Research Institute, Inc.
phone: 919-433-1600
e-mail: RMorgan@kowaus.com



Responsible Party: Kowa Research Institute, Inc.
ClinicalTrials.gov Identifier: NCT01301066     History of Changes
Other Study ID Numbers: NK-104-4.05US
Study First Received: February 18, 2011
Results First Received: February 10, 2014
Last Updated: March 27, 2014
Health Authority: United States: Food and Drug Administration